المؤلفون: Giusy Schipani, Steven P. Nisticò, Pietro Quaglino, Simone Ribero, Giuseppe Gallo, Vincenzo Maione, Giampiero Girolomoni, Paolo Rosina, Mauro Alaibac, Francesco Messina, Alessandro Gatti, Giuseppe Stinco, Cinzia Buligan, Sara Bassoli, Francesca Farnetani, Alessandro Borghi, Davide Melandri, Riccardo Sirna, Luca Feci, Stefano Simonetti, Luca Stingeni, Annamaria Offidani, Valerio Brisigotti, Anna Campanati, Stefano Calvieri, Giulia Spallone, Elisabetta Botti, Vincenzo Panasiti, Gianluca Pagnanelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Claudia Costa, Vincenzo Schirripa, Francesco Borgia, Laura Atzori, Elisabetta Scali, Maria Passante, Fabrizio Guarneri, Cataldo Patruno

المصدر: JEADV Clinical Practice, Vol 3, Iss 1, Pp 76-85 (2024)

مصطلحات موضوعية: head–neck melanoma, location of melanoma, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923

الوصف: Abstract Background Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation. Objectives In this multicentric study, data regarding head–neck melanoma (HNM) have been revised. Methods The design of the study included two main phases. In this retrospective study, data regarding HNM have been collected and analysed. Results In summary, our data suggest that the posterior neck is the area most affected by thicker melanomas. Cheeks and neck melanoma are associated with reduced disease‐free years of life and overall survival compared with all other sites of HNM. Conclusions This study provides useful information in defining the clinical features of HNM, thus improving diagnosis and treatment strategies.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2768-6566Test

الوصول الحر: https://doaj.org/article/3268f3c84e894b2f83d099b916a236a1Test

المؤلفون: Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, the BRIGHT Study Group

المصدر: JEADV Clinical Practice, Vol 2, Iss 4, Pp 739-752 (2023)

مصطلحات موضوعية: brodalumab, effectiveness, observational, psoriasis, real‐world, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923

الوصف: Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for systemic treatment. Objectives This study evaluated the achievement and maintenance of therapeutic response for 1 year in psoriasis patients treated with brodalumab in the Italian clinical practice. Methods Real‐world, multicenter, observational, retrospective and prospective study. The retrospective phase ranged from enrolment visit to initiation of brodalumab (12 ± 4 weeks before). The prospective phase ranged from enrolment to a routine follow‐up visit set after 52 ± 4 weeks. Results One hundred eighty‐four patients were eligible and 164 completed the observation period (median 11.9 months; Q1–Q3: 11.4–12.3). At enrolment, the mean duration of disease was 13.9 years (standard deviation; 13.3), 94% of patients (N = 172) had ≥1 clinical manifestation of psoriasis, mainly erythema and itching, and 95.6% had received ≥1 antipsoriatic treatment before brodalumab. Patients who reached an absolute Psoriasis Area and Severity Index (PASI) score ≤3 at week 12 and maintained it ≤3 through week 52 were 97 (64.7%). At week 12, 72.7% of patients achieved PASI 75, 54.5% PASI 90 and 42.0% PASI 100. At Week 52, 92.9% of patients achieved PASI 75, 84.4% PASI 90 and 61.7% PASI 100. A static Physician's Global Assessment (sPGA) score = 0 was obtained by 55.0% of patients after 12 weeks of brodalumab and by 77.0% after 52 weeks. A Dermatology Life Quality Index ≤1 was reported by 71.9% of patients after 12 weeks and by 89.9% after 52 weeks of treatment. No significant outcome differences were shown among patient subgroups defined by previous antipsoriatic treatments (none, systemic other than biologics or biologic) at either brodalumab initiation or any of the subsequent study visits. Conclusions In this real‐world setting, brodalumab was rapidly effective on skin lesions and quality of life both in biologic‐naïve and biologic‐experienced moderate‐to‐severe psoriasis patients, with a favourable safety profile.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2768-6566Test

الوصول الحر: https://doaj.org/article/32e63bc3aabf482aa696331c742f6d4bTest

المؤلفون: Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E

المصدر: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 3561-3574 (2023)

مصطلحات موضوعية: psoriasis, secukinumab, real-world evidence, drug survival, supreme, Dermatology, RL1-803

الوصف: Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,† Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Section of Dermatology, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genova, Italy; 14Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 15Section of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 16Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 17Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 18Section of Dermatology, Department of Medical and Surgical Specialties, University of Catania, Catania, Italy; 19Dermatology Clinic of Terni, University of Perugia, Perugia, Italy; 20Section of Dermatology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 21Department of Health Sciences, Magna Graecia University, Catanzaro, Italy; 22Department of Medicine and Surgery, University of Parma, Parma, Italy; 23Section of Dermatology, Department of Biotechnological and Applied Clinical Science, University of L’Aquila, L’Aquila, Italy; 24Department of Dermatology, Istituto Dermopatico dell’Immacolata - IRCCS, Roma, Italy; 25Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Dermatology Unit, “Daniele Innocenzi”, Asl Latina, Italy; 26Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 27Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; 28Dermatology Unit, Lucca Azienda USL Toscana Nord Ovest, Pisa, Italy; 29Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; 30Department of Dermatology, University of Trieste, Trieste, Italy; 31Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 32Department of Dermatology, University of Bari, Bari, Italy; 33Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; 34Dermatology Unit, Vito Fazzi Hospital, Lecce, Italy; 35Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy; 36Dermatology Unit, IRCCS IO Galeazzi, Milan, Italy; 37Dermatological Clinic, Polytechnic University of the Marche Region, Ancona, Italy; 38Department of Dermatology, Istituto Dermatologico San Gallicano - IRCCS, Roma, Italy; 39Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 40Novartis Farma SpA, Origgio, Italy; 41National Centre for Healthcare Research and Pharmacoepidemiology, Milan, Italy; 42Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy†Gabriella Fabbrocini passed away on 3 March 2023Correspondence: Filomena Russo, Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy, Email file.russo@libero.itPurpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings.Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.Keywords: psoriasis, secukinumab, real-world evidence, drug survival, SUPREME

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/long-term-drug-survival-and-effectiveness-of-secukinumab-in-patients-w-peer-reviewed-fulltext-article-CCIDTest; https://doaj.org/toc/1178-7015Test

الوصول الحر: https://doaj.org/article/115768c008944ac5b86654ed48f517a0Test

المؤلفون: Gargiulo L, Ibba L, Malagoli Piergiorgio, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera C G, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani F M, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano A V, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo. A, Narcisi A

المساهمون: Gargiulo, L, Ibba, L, Malagoli, Piergiorgio, Amoruso, F, Argenziano, G, Balato, A, Bardazzi, F, Burlando, M, Carrera, C G, Damiani, G, Dapavo, P, Dini, V, Fabbrocini, G, Franchi, C, Gaiani, F M, Girolomoni, G, Guarneri, C, Lasagni, C, Loconsole, F, Marzano, A V, Maurelli, M, Megna, M, Orsini, D, Sampogna, F, Travaglini, M, Valenti, M, Costanz, o. A., Narcisi, A

مصطلحات موضوعية: risankizumab super responder profile identified by long-term real-life observation-IL PSO

الوصف: Risankizumab is a humanized monoclonal antibody that targets interleukin (IL-)23, approved for the treatment of moderate-to-severe plaque psoriasis, which has shown efficacy in both clinical trials and real-world experiences.1–4 However, there is still limited knowledge regarding which patients could benefit the most from the therapy with risankizumab

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37611277; info:eu-repo/semantics/altIdentifier/wos/WOS:001069616400001; volume:38; issue:1; firstpage:113; lastpage:116; numberofpages:4; journal:JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; https://hdl.handle.net/11562/1116595Test

الإتاحة: https://doi.org/10.1111/jdv.19464Test
https://hdl.handle.net/11562/1116595Test

المؤلفون: Stingeni, Luca, Chiricozzi, Andrea, Calzavara-Pinton, Piergiacomo, Napolitano, Maddalena, Peris, Ketty, Schena, Donatella, Patruno, Cataldo, Rossi, Mariateresa, Foti, Caterina, Fargnoli, Maria C., Corazza, Monica, Ferrucci, Silvia M., Pigatto, Paolo D., Romanelli, Marco, Fabbrocini, Gabriella, Girolomoni, Giampiero, Passante, Maria, Romita, Paolo, Esposito, Maria, Schettini, Natale, Marzano, Angelo V., Tonini, Giulia, Marietti, Rossella, Casciola, Gabriele, Argenziano, Giuseppe, Hansel, Katharina, Antonelli, Elettra, Antonelli, Flaminia, Artelli, Grazia L., Barei, Francesca, Berardinis, Andrea, Bianchi, Leonardo, Borghi, Alessandro, Dastoli, Stefano, Vico, Francesco, Mennuni, Biagina G., Michelucci, Alessandra, Pascucci, Enrico, Bianchi, Luca, AtopyReg Study Group

المساهمون: Stingeni, L, Chiricozzi, A, Calzavara-Pinton, P, Napolitano, M, Peris, K, Schena, D, Patruno, C, Rossi, M, Foti, C, Fargnoli, Mc, Corazza, M, Ferrucci, Sm, Pigatto, Pd, Romanelli, M, Fabbrocini, G, Girolomoni, G, Passante, M, Romita, P, Esposito, M, Schettini, N, Marzano, Av, Tonini, G, Marietti, R, Casciola, G, Argenziano, G, Hansel, K, Antonelli, E, Antonelli, F, Artelli, Gl, Barei, F, Berardinis, A, Bianchi, L, Borghi, A, Dastoli, S, Vico, F, Mennuni, Bg, Michelucci, A, Pascucci, E, AtopyReg Study, G

مصطلحات موضوعية: Settore MED/35

الوصف: background and objective atopyReg((R)) is a multicenter, prospective, observational, non-profit cohort study on moderate-tosevere atopic dermatitis in adults promoted in 2018 by the Italian society of dermatology and Venereology (SIDeMaST). we aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis.methods patients were selected based on the following inclusion criteria: age >= 18 years; eczema area and severity Index score >= 7 or a numeric rating scale sleep loss score = 7, or a dermatology life quality Index score >= 10. score >= 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a numeric rating scale itchDemographic and clinical data at baseline were recorded and analyzed. results a total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18-90 years) were enrolled by 12 Italian dermatology units between January 2019 and november 2022. skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). mean eczema area and severity Index score was 22.3, mean dermatology life quality Index value was 17.6, mean patient oriented Eczema measure score was 13.1, and mean numeric rating scale itch and sleep loss scores were 7.6 and 5.9, respectively. previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients.conclusions this baseline data analysis deriving from atopyReg((R)) provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients' quality of life.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37725229; info:eu-repo/semantics/altIdentifier/wos/WOS:001067926100001; volume:25; issue:1; firstpage:149; lastpage:160; numberofpages:12; journal:AMERICAN JOURNAL OF CLINICAL DERMATOLOGY; https://hdl.handle.net/2108/359723Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85171472256

الإتاحة: https://doi.org/10.1007/s40257-023-00819-yTest
https://hdl.handle.net/2108/359723Test

المؤلفون: Schipani G., Nistico S. P., Quaglino P., Ribero S., Gallo G., Maione V., Girolomoni G., Rosina P., Alaibac M., Messina F., Gatti A., Stinco G., Buligan C., Bassoli S., Farnetani F., Borghi A., Melandri D., Sirna R., Feci L., Simonetti S., Stingeni L., Offidani A., Brisigotti V., Campanati A., Calvieri S., Spallone G., Botti E., Panasiti V., Pagnanelli G., Scalvenzi M., Fabbrocini G., Costa C., Schirripa V., Borgia F., Atzori L., Scali E., Passante M., Guarneri F., Patruno C.

المساهمون: Schipani, G., Nistico, S. P., Quaglino, P., Ribero, S., Gallo, G., Maione, V., Girolomoni, G., Rosina, P., Alaibac, M., Messina, F., Gatti, A., Stinco, G., Buligan, C., Bassoli, S., Farnetani, F., Borghi, A., Melandri, D., Sirna, R., Feci, L., Simonetti, S., Stingeni, L., Offidani, A., Brisigotti, V., Campanati, A., Calvieri, S., Spallone, G., Botti, E., Panasiti, V., Pagnanelli, G., Scalvenzi, M., Fabbrocini, G., Costa, C., Schirripa, V., Borgia, F., Atzori, L., Scali, E., Passante, M., Guarneri, F., Patruno, C.

مصطلحات موضوعية: head–neck melanoma, location of melanoma

الوصف: Background: Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation. Objectives: In this multicentric study, data regarding head–neck melanoma (HNM) have been revised. Methods: The design of the study included two main phases. In this retrospective study, data regarding HNM have been collected and analysed. Results: In summary, our data suggest that the posterior neck is the area most affected by thicker melanomas. Cheeks and neck melanoma are associated with reduced disease-free years of life and overall survival compared with all other sites of HNM. Conclusions: This study provides useful information in defining the clinical features of HNM, thus improving diagnosis and treatment strategies.

العلاقة: volume:3; issue:1; firstpage:76; lastpage:85; numberofpages:10; journal:JEADV CLINICAL PRACTICE; https://hdl.handle.net/11573/1706731Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85186390171

الإتاحة: https://doi.org/10.1002/jvc2.250Test
https://hdl.handle.net/11573/1706731Test

المؤلفون: Prignano, Francesca, Argenziano, Giuseppe, Bardazzi, Federico, Borroni, Riccardo G., Brunasso, Alexandra M. G., Burlando, Martina, Cagni, Anna Elisabetta, Campione, Elena, Cinotti, Elisa, Colonna, Fabrizio, Cuccia, Aldo, Dastoli, Stefano, De Pasquale, Rocco, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Fabbrocini, Gabriella, Galluzzi, Claudia, Giacchetti, Alfredo, Giofrè, Claudia, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Montesu, Maria Antonia, Pella, Paolo, Piaserico, Stefano, Pigatto, Paolo, Richetta, Antonio Giovanni, Scuotto, Adriana, Stroppiana, Elena, Venturini, Marina, Vinci, Anna Stefania, Zichichi, Leonardo, Fargnoli, Maria Concetta

المساهمون: Prignano, Francesca, Argenziano, Giuseppe, Bardazzi, Federico, Borroni, Riccardo G., Brunasso, Alexandra M. G., Burlando, Martina, Cagni, Anna Elisabetta, Campione, Elena, Cinotti, Elisa, Colonna, Fabrizio, Cuccia, Aldo, Dastoli, Stefano, De Pasquale, Rocco, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Fabbrocini, Gabriella, Galluzzi, Claudia, Giacchetti, Alfredo, Giofrè, Claudia, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Montesu, Maria Antonia, Pella, Paolo, Piaserico, Stefano, Pigatto, Paolo, Richetta, Antonio Giovanni, Scuotto, Adriana, Stroppiana, Elena, Venturini, Marina, Vinci, Anna Stefania, Zichichi, Leonardo, Fargnoli, Maria Concetta

مصطلحات موضوعية: dermatologist perspective, patient, psoriasi, quality of life, surveys and questionnaire, treatment, wellbeing

الوصف: A nationwide cross-sectional online survey was administered to dermatologists managing patients with moderate-to-severe plaque psoriasis across Italy to obtain real-world dermatologists' perspectives on the impact of psoriasis and its treatment on patients' daily lives and quality of life (QoL). A total of 91 dermatologists (aged 39.1 +/- 11.2 years) completed a 31-question survey and workshop sessions were undertaken in order to identify the best management approach to achieve patient wellbeing. Social (4.2 +/- 0.1), physical (4.26 +/- 0.2) and mental components (4.1 +/- 0.3) were rated by dermatologists as contributing to patient wellbeing to similar extents. While a high proportion (85.4%; rating of 4.3 out of 5) of dermatologists felt that they considered the QoL of patients, a lower proportion (69.6%; rating of 3.7 out of 5) felt that patients were satisfied in this regard. The psoriasis area and severity index and body surface area were the instruments most frequently used to assess the physical domain, while interviews/questions and the dermatology life quality index were used to assess social and mental domains, with only 60% of dermatologists following up on these aspects. The importance of investigating the presence of comorbidities was recognized but not always carried out by many dermatologists, (>70%), particularly for obesity and anxiety/depression. This survey identified key components contributing to barriers impacting on the QoL of patients with moderate-to-severe psoriasis from the perspective of the dermatologist.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001141481800001; volume:13; issue:1; firstpage:101; numberofpages:18; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/11388/324209Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85181888242

الإتاحة: https://doi.org/10.3390/jcm13010101Test
https://hdl.handle.net/11388/324209Test

المؤلفون: Cacciapuoti, S, Scala, E, Luciano, MA, Marasca, C, Megna, M, Caiazzo, G, Parisi, M, Quaranta, M, Fabbrocini, G

المصدر: Italian journal of dermatology and venereology. 158(2):124-127

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:153231298Test

المؤلفون: Di Caprio, R, Sacchelli, L, Di Spigna, G, Ricciardone, M, Bardazzi, F, Ladogana, P, Scala, E, Fabbrocini, G, Covelli, B, Balato, A, Postiglione, L

المصدر: European journal of dermatology : EJD. 33(1):12-18

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:153038670Test

المؤلفون: Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M

المصدر: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 2637-2644 (2023)

مصطلحات موضوعية: brodalumab, psoriasis, difficult-to-treat areas, biologic drugs, efficacy, Dermatology, RL1-803

الوصف: Sara Cacciapuoti,* Luca Potestio,* Gianluca Guerrasio, Gabriella Fabbrocini ,† Massimiliano Scalvenzi, Angelo Ruggiero,* Giuseppina Caiazzo,* Matteo Megna* Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy*These authors contributed equally to this work†Professor Gabriella Fabbrocini passed away on 3rd March 2023Correspondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email angeloruggiero1993@libero.itBackground: Recent knowledge of psoriasis pathogenesis has led to the development of selective drugs. Among these, brodalumab is a monoclonal antibody targeting the interleukin (IL)-17A receptor approved for the treatment of moderate-to-severe plaque psoriasis. Biologics may be considered in patients with milder diseases in case of active psoriatic arthritis, severe impact on patient’s quality of life, and involvement of sensitive and difficult-to-treat areas. These skin locations commonly require systemic drugs. Recently, psoriasis severity monitoring has also changed. Indeed, the clinical evaluation by means of specific efficacy scores was combined with serological evaluation by means of the assay of specific inflammatory biomarkers.Methods: An observational study enrolled patients affected by moderate-to-severe plaque psoriasis involving difficult-to-treat areas, undergoing treatment with brodalumab to evaluate the effectiveness and safety of brodalumab in patients with psoriasis affecting difficult-to-treat areas (scalp and palmoplantar regions). Secondary outcomes were the assessment of the development of serum markers of inflammation during the treatment period as well as the evaluation of the dermoscopic features of the affected sites to quantify disease activity and response to treatment.Results: Twenty-five patients were included in the study. A statistically significant reduction from baseline in PASI, PSSI, ppPASI and DLQI values as early as week 24 was observed, with further improvement up to week 52. Plasma levels of MMP-3, VEGF-A, and hs-PCR decreased during treatment from week 0 to week 52.Conclusion: Our real-life experience suggests brodalumab as a valuable option for the management of psoriasis located in difficult-to-treat areas. Moreover, our study highlights that the use of brodalumab reduces the plasmatic levels of inflammatory biomarkers (MMP-3, VEGF-A and hs-PCR), showing how the drug modulates the skin inflammatory response by reducing systemic inflammation.Keywords: brodalumab, psoriasis, difficult-to-treat areas, biologic drugs, efficacy

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/effectiveness-of-brodalumab-in-patients-with-moderate-to-severe-plaque-peer-reviewed-fulltext-article-CCIDTest; https://doaj.org/toc/1178-7015Test

الوصول الحر: https://doaj.org/article/7a6b415202844f2bbe913645464a45f8Test